Unum (UNM) Q4 2024 Earnings Call Transcript

Unum Group delivered 10.2% adjusted EPS growth in 2024 to $8.44, above initial guidance, while core ROE topped 20% and the company raised its dividend 15% and repurchased about $1 billion of stock. Management guided to another strong year in 2025, with adjusted EPS expected to rise 8%-12%, free cash flow of $1.3 billion-$1.6 billion, and buybacks of $500 million-$1 billion. Capital remained very strong at $2 billion of holdco cash and a 430% RBC ratio, while the LTC block required no capital for the first time in years.

Analysis

UNM’s setup is unusually clean for an insurer: the core franchise is compounding while the legacy LTC drag is transitioning from a capital sink to a self-funding option. That matters because once a long-tail liability stops consuming capital, incremental statutory earnings can be recycled almost entirely into buybacks/dividends, which mechanically raises per-share growth even if the top line only grows mid-single digits. The market is likely still underwriting some residual “legacy block overhang” discount, but management’s capital language suggests the balance sheet is now more of a coiled spring than a constraint.

The bigger second-order effect is competitive: pricing discipline in disability and life can be maintained longer when the seller is winning through embedded workflow, leave management, and enrollment infrastructure rather than pure rate. That shifts the moat from actuarial pricing to distribution plumbing, which is harder for smaller peers and benefit boutiques to replicate quickly. It also explains why persistency can stay high even in a competitive market—customers are less likely to re-bid when the insurer is embedded in HR operations and employee workflow.

The key risk is that the market extrapolates too much of 2024’s favorable claims/recovery trend into 2025, while voluntary benefits and closed-block volatility add noise. If claims normalize faster than expected or pricing competition heats up in the next renewal cycle, the stock could de-rate from “quality compounder with buybacks” back to “cyclical underwriting story.” The catalyst window is the next 2–3 quarters, where investors will be able to test whether the low-60s disability thesis holds through renewals and whether capital deployment stays aggressive if M&A remains mostly optional.

Consensus may be missing that the real upside is not just earnings growth, but mix shift: capital that used to defend LTC can now lever equity returns in the core business. If management executes even modestly on selective M&A around distribution/tech, the market could start assigning a higher multiple to a business that looks more like a platform than a pure insurer.

Key Decisions for Investors

• Long UNM outright for a 3–6 month horizon; use any post-earnings digestion or broad financials weakness to add. Risk/reward skews positive if capital returns remain near the high end of guidance and disability loss ratios stay in the low 60s.
• Pair trade: long UNM / short a lower-quality life/disability peer with weaker distribution and less capital flexibility (e.g., CNO or AFL if you want more conservative balance-sheet comparability). Thesis: UNM’s buyback-backed EPS growth should outpace peers whose growth is more dependent on underwriting normalization.
• Sell downside volatility in UNM via 3–6 month put spreads if implied vol stays elevated on LTC headlines. The market is overpaying for tail risk that management is actively de-risking, while realized capital generation supports the stock.
• If you need a catalyst trade, buy UNM on the next quarterly print only if management reaffirms 2025 buybacks and no LTC capital needs; otherwise wait for a pullback. The stock should respond more to capital deployment updates than to small underwriting noise.
• Avoid chasing upside via out-of-the-money calls unless you have a specific M&A catalyst. The cleaner expression is cash equity or a limited-risk call spread, since multiple expansion is likely gradual rather than explosive.